Venom-Derived Peptides from Snails, Snakes, and Spiders Show Promise as Non-Opioid Pain Treatments

The review identifies multiple families of venom-derived analgesic peptides from cone snails, snakes, sea anemones, tarantulas, scorpions, and spiders. These peptides target key peripheral pain receptors including TRPV1, TRPV2, voltage-gated sodium, calcium, and potassium channels, and acid-sensing ion channels (ASICs). Animal studies demonstrate robust analgesic effects across various pain types. The specificity of these venom peptides for individual ion channel subtypes gives them potential advantages over existing analgesics.

Narrative review of the literature on venom-derived peptides that target peripheral pain pathways. The review covers the pathophysiology of peripheral pain receptors, catalogs analgesic peptides from various venomous species, and summarizes their mechanisms of action and preclinical efficacy data.

The opioid crisis has created urgent demand for non-opioid analgesics that can effectively treat pain without addiction risk. Venom-derived peptides represent one of nature's most refined approaches to modulating nervous system signaling. One venom peptide (ziconotide, from cone snails) is already FDA-approved for severe chronic pain, proving the concept works. This review maps the broader landscape of venom peptides that could become the next generation of pain medications.

Nature has spent millions of years evolving venom peptides that precisely manipulate ion channels — the exact molecular targets that pain researchers are trying to drug. The success of ziconotide (from cone snail venom) validates this approach, and the thousands of venom peptides yet to be fully characterized represent a vast untapped pharmacological resource. As peptide drug delivery and manufacturing technologies improve, more venom-derived analgesics could reach clinical use, offering targeted pain relief that avoids the addiction and tolerance problems of opioids.

This is a narrative review without systematic methodology. Most evidence for venom-derived analgesic peptides comes from animal models, and translation to human pain conditions is uncertain. Venom peptides often require injection (some intrathecally), limiting practical clinical use. Peptide stability, manufacturing costs, and potential immunogenicity are ongoing challenges. The review focuses on peripheral pain, and efficacy against central pain conditions is less explored.